Preventive IVIG Therapy for Congenital Heart Block (PITCH)
Preventive IVIG Therapy for Congenital Heart Block (The PITCH Study)
Sponsor: Lupus Research Alliance
Listed as NCT00460928, this EARLY_PHASE1 trial focuses on Autoantibody-associated Heart Block and Congenital Heart Block and remains completed. Sponsored by Lupus Research Alliance, it has been updated 11 times since 2007, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed EARLY_PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed EARLY_PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed EARLY_PHASE1
-
Oct 2019 — Jan 2021 [monthly]
Completed EARLY_PHASE1
-
Jun 2019 — Oct 2019 [monthly]
Completed EARLY_PHASE1
▶ Show 6 earlier versions
-
Mar 2019 — Jun 2019 [monthly]
Completed EARLY_PHASE1
Phase: PHASE2_PHASE3 → EARLY_PHASE1
-
Jun 2018 — Mar 2019 [monthly]
Completed PHASE2_PHASE3
-
Feb 2018 — Jun 2018 [monthly]
Completed PHASE2_PHASE3
-
Jun 2017 — Feb 2018 [monthly]
Completed PHASE2_PHASE3
-
Apr 2017 — Jun 2017 [monthly]
Completed PHASE2_PHASE3
-
Jan 2017 — Apr 2017 [monthly]
Completed PHASE2_PHASE3
First recorded
Apr 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Lupus Research Alliance
- NYU Langone Health
For direct contact, visit the study record on ClinicalTrials.gov .